Pembrolizumab shows promise in treatment of mesothelioma

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study. The work is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease. (Mehr in: Cancer News — ScienceDaily)